These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

372 related articles for article (PubMed ID: 12628477)

  • 1. Differential effects of YM440 a hypoglycemic agent on binding to a peroxisome proliferator-activated receptor gamma and its transactivation.
    Kurosaki E; Nakano R; Shimaya A; Yoshida S; Ida M; Suzuki T; Shibasaki M; Shikama H
    Biochem Pharmacol; 2003 Mar; 65(5):795-805. PubMed ID: 12628477
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The novel hypoglycemic agent YM440 normalizes hyperglycemia without changing body fat weight in diabetic db/db mice.
    Shimaya A; Kurosaki E; Nakano R; Hirayama R; Shibasaki M; Shikama H
    Metabolism; 2000 Mar; 49(3):411-7. PubMed ID: 10726922
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Rosiglitazone induction of Insig-1 in white adipose tissue reveals a novel interplay of peroxisome proliferator-activated receptor gamma and sterol regulatory element-binding protein in the regulation of adipogenesis.
    Kast-Woelbern HR; Dana SL; Cesario RM; Sun L; de Grandpre LY; Brooks ME; Osburn DL; Reifel-Miller A; Klausing K; Leibowitz MD
    J Biol Chem; 2004 Jun; 279(23):23908-15. PubMed ID: 15073165
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A novel insulin sensitizer acts as a coligand for peroxisome proliferator-activated receptor-alpha (PPAR-alpha) and PPAR-gamma: effect of PPAR-alpha activation on abnormal lipid metabolism in liver of Zucker fatty rats.
    Murakami K; Tobe K; Ide T; Mochizuki T; Ohashi M; Akanuma Y; Yazaki Y; Kadowaki T
    Diabetes; 1998 Dec; 47(12):1841-7. PubMed ID: 9836514
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A novel method for analysis of nuclear receptor function at natural promoters: peroxisome proliferator-activated receptor gamma agonist actions on aP2 gene expression detected using branched DNA messenger RNA quantitation.
    Burris TP; Pelton PD; Zhou L; Osborne MC; Cryan E; Demarest KT
    Mol Endocrinol; 1999 Mar; 13(3):410-7. PubMed ID: 10076998
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Coordinate regulation of the expression of the fatty acid transport protein and acyl-CoA synthetase genes by PPARalpha and PPARgamma activators.
    Martin G; Schoonjans K; Lefebvre AM; Staels B; Auwerx J
    J Biol Chem; 1997 Nov; 272(45):28210-7. PubMed ID: 9353271
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Rosiglitazone (BRL49653), a PPARgamma-selective agonist, causes peroxisome proliferator-like liver effects in obese mice.
    Edvardsson U; Bergström M; Alexandersson M; Bamberg K; Ljung B; Dahllöf B
    J Lipid Res; 1999 Jul; 40(7):1177-84. PubMed ID: 10393202
    [TBL] [Abstract][Full Text] [Related]  

  • 8. PPARalpha activation by Wy 14643 induces transactivation of the rat UCP-1 promoter without increasing UCP-1 mRNA levels and attenuates PPARgamma-mediated increases in UCP-1 mRNA levels induced by rosiglitazone in fetal rat brown adipocytes.
    Teruel T; Clapham JC; Smith SA
    Biochem Biophys Res Commun; 1999 Oct; 264(2):311-5. PubMed ID: 10529360
    [TBL] [Abstract][Full Text] [Related]  

  • 9. PAT5A: a partial agonist of peroxisome proliferator-activated receptor gamma is a potent antidiabetic thiazolidinedione yet weakly adipogenic.
    Misra P; Chakrabarti R; Vikramadithyan RK; Bolusu G; Juluri S; Hiriyan J; Gershome C; Rajjak A; Kashireddy P; Yu S; Surapureddi S; Qi C; Zhu YJ; Rao MS; Reddy JK; Ramanujam R
    J Pharmacol Exp Ther; 2003 Aug; 306(2):763-71. PubMed ID: 12730351
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Differential activation of peroxisome proliferator-activated receptor-gamma by troglitazone and rosiglitazone.
    Camp HS; Li O; Wise SC; Hong YH; Frankowski CL; Shen X; Vanbogelen R; Leff T
    Diabetes; 2000 Apr; 49(4):539-47. PubMed ID: 10871190
    [TBL] [Abstract][Full Text] [Related]  

  • 11. FK614, a novel peroxisome proliferator-activated receptor gamma modulator, induces differential transactivation through a unique ligand-specific interaction with transcriptional coactivators.
    Fujimura T; Sakuma H; Konishi S; Oe T; Hosogai N; Kimura C; Aramori I; Mutoh S
    J Pharmacol Sci; 2005 Dec; 99(4):342-52. PubMed ID: 16314690
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Regulation of gene expression by activation of the peroxisome proliferator-activated receptor gamma with rosiglitazone (BRL 49653) in human adipocytes.
    Rieusset J; Auwerx J; Vidal H
    Biochem Biophys Res Commun; 1999 Nov; 265(1):265-71. PubMed ID: 10548525
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Activation of the nuclear receptor peroxisome proliferator-activated receptor gamma promotes brown adipocyte differentiation.
    Tai TA; Jennermann C; Brown KK; Oliver BB; MacGinnitie MA; Wilkison WO; Brown HR; Lehmann JM; Kliewer SA; Morris DC; Graves RA
    J Biol Chem; 1996 Nov; 271(47):29909-14. PubMed ID: 8939934
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A new thiazolidinedione, NC-2100, which is a weak PPAR-gamma activator, exhibits potent antidiabetic effects and induces uncoupling protein 1 in white adipose tissue of KKAy obese mice.
    Fukui Y; Masui S; Osada S; Umesono K; Motojima K
    Diabetes; 2000 May; 49(5):759-67. PubMed ID: 10905484
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Euglycemic and hypolipidemic activity of PAT5A: a unique thiazolidinedione with weak peroxisome proliferator activated receptor gamma activity.
    Vikramadithyan RK; Chakrabarti R; Misra P; Premkumar M; Kumar SK; Rao CS; Ghosh A; Reddy KN; Uma C; Rajagopalan R
    Metabolism; 2000 Nov; 49(11):1417-23. PubMed ID: 11092504
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Thiazolidinedione exposure increases the expression of uncoupling protein 1 in cultured human preadipocytes.
    Digby JE; Montague CT; Sewter CP; Sanders L; Wilkison WO; O'Rahilly S; Prins JB
    Diabetes; 1998 Jan; 47(1):138-41. PubMed ID: 9421389
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Differential effects of rexinoids and thiazolidinediones on metabolic gene expression in diabetic rodents.
    Singh Ahuja H; Liu S; Crombie DL; Boehm M; Leibowitz MD; Heyman RA; Depre C; Nagy L; Tontonoz P; Davies PJ
    Mol Pharmacol; 2001 Apr; 59(4):765-73. PubMed ID: 11259621
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A novel peroxisome proliferator-activated gamma (PPAR gamma) agonist, CLX-0921, has potent antihyperglycemic activity with low adipogenic potential.
    Dey D; Medicherla S; Neogi P; Gowri M; Cheng J; Gross C; Sharma SD; Reaven GM; Nag B
    Metabolism; 2003 Aug; 52(8):1012-8. PubMed ID: 12898466
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Peroxisome proliferator-activated receptor-gamma represses GLUT4 promoter activity in primary adipocytes, and rosiglitazone alleviates this effect.
    Armoni M; Kritz N; Harel C; Bar-Yoseph F; Chen H; Quon MJ; Karnieli E
    J Biol Chem; 2003 Aug; 278(33):30614-23. PubMed ID: 12777391
    [TBL] [Abstract][Full Text] [Related]  

  • 20. YM268 increases the glucose uptake, cell differentiation, and mRNA expression of glucose transporter in 3T3-L1 adipocytes.
    Shimaya A; Kurosaki E; Shioduka K; Nakano R; Shibasaki M; Shikama H
    Horm Metab Res; 1998 Sep; 30(9):543-8. PubMed ID: 9808320
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.